Overview

A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough

Status:
NOT_YET_RECRUITING
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled Phase Ib/II clinical trial to evaluate the effectiveness, safety, tolerability and pharmacokinetics (PK) of TCR1672 Tablets in patients with refractory chronic cough.
Phase:
PHASE1
Details
Lead Sponsor:
Beijing Tide Pharmaceutical Co., Ltd